Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression In Rheumatoid Arthritis Models By Selective Inhibition Of The Immunoproteasome
Proteolix, Inc. announced that in an article published in Nature Medicine, Proteolix"s selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis.

Implanted Defibrillators: New Recommendations For Drivers With ICDs
Patients with an Implantable Cardioverter Defibrillator (ICD) have an ongoing risk of sudden incapacitation that might cause harm to others while driving a car. Driving restrictions are imposed making these recommendations an important guideline for patients.
News of the day
EUROPACE Raises Remote Monitoring Profile
"Moving to a more continuous follow-up approach would have the tremendous advantages of enhancing patient safety, decreasing physician and nurse work load, and allowing health staff to focus on medical emergencies," urged Professor Angelo Auricchio, from the European Heart Rhythm Association (EHRA) and official spokesperson of the European Society of Cardiology (ESC), adding that such systems may have the additional advantage of being more cost effective for health care providers.
Mental Health

Namibia Close To Reaching Some MDGs

Namibia"s recently released second MDG Report 2008 finds that the country is making progress toward achieving some of the U.N. Millennium Development Goal (MDG) targets. However, the Prime Minister says the global economic situation could reverse progress and notes that the country is behind on some health-related targets, New Era reports. The report says the country has achieved goals pertaining to the reduction of HIV/AIDS prevalence rates in people between the ages of 15 and 19 years old, malaria incidence and others. "These targets fall under MDGs relating to eradicating extreme poverty and hunger, achieving universal primary education, promoting gender equality and empowering women, combating HIV/AIDS, malaria and other diseases," New Era writes. Prime Minister Nahas Angula said the country must focus on education, agriculture and health in order to achieve other MDG targets. He highlighted the need to focus on primary health care, malnutrition, sanitation and maternal health. The report noted that Namibia likely will not reach the MDG targets for maternal and infant mortality. "Something must be done. Even if it means training young people to train their fellow young women on prenatal care and Traditional Birth Attendant to assist with deliveries, we should do it," Angula said. Acting U.N. Resident Coordinator Joyce Mends-Cole said the global economic situation "will directly affect" efforts to achieve MDG targets. "In comparison with past performance, the poor unemployment picture suggests that the rate of progress will even be slower," she said (New Era, 6/23). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009